Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use
R Teschke, G Danan - International Journal of Molecular Sciences, 2023 - mdpi.com
Clinical and mechanistic considerations in idiosyncratic drug-induced liver injury (iDILI)
remain challenging topics when they are derived from mere case narratives or iDILI cases …
remain challenging topics when they are derived from mere case narratives or iDILI cases …
Cancer bioenergetics and tumor microenvironments—Enhancing chemotherapeutics and targeting resistant niches through nanosystems
Simple Summary Cancer remains a major killer of the human population. Current cancer
diagnostic and therapeutic methods are associated with shortcomings of limited targetability …
diagnostic and therapeutic methods are associated with shortcomings of limited targetability …
YES1 Kinase Mediates the Membrane Removal of Rescued F508del-CFTR in Airway Cells by Promoting MAPK Pathway Activation via SHC1
Recent developments in CFTR modulator drugs have had a significant transformational
effect on the treatment of individuals with Cystic Fibrosis (CF) who carry the most frequent …
effect on the treatment of individuals with Cystic Fibrosis (CF) who carry the most frequent …
[HTML][HTML] From spotlight to shadow: ALK inhibitor-induced acute liver failure in a patient with non-small cell lung cancer
SŞ Juncu, AV Trifan, H Minea, RI Avram… - Archive of Clinical …, 2023 - ncbi.nlm.nih.gov
Novel oncological therapies substantially improved the prognosis of cancer patients.
Immunotherapies (immune checkpoint inhibitors) and targeted therapies (tyrosine kinase …
Immunotherapies (immune checkpoint inhibitors) and targeted therapies (tyrosine kinase …
Vascular endothelial growth factor receptor tyrosine kinase inhibitors associated hepatotoxicity: An Analysis of the FDA Adverse Event Reporting System
H Zheng, K Zhou, Z Zheng, M Xiao, F Wen, F Wu, B Wu - 2023 - researchsquare.com
Vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR-TKIs) are widely used
in cancer. Despite the growing number of reported cases of hepatotoxicity resulting from the …
in cancer. Despite the growing number of reported cases of hepatotoxicity resulting from the …